PTGS2 and neoplasm: In several murine and hamster models of head and neck cancer, administration of the COX-2 inhibitor celecoxib decreased expression of vascular endothelial growth factor (VEGF) and survivin, increased tumor cell apoptosis and decreased tumor growth (18–20).